

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+5.62%
-3.26%
+11.27%
+19.34%
-2.31%
SNY
Sanofi
$49.52
Strengths

Earnings are forecast to grow

Trading below its fair value
Chart
$45.54 (+8.74%)
$45.66 (+8.45%)
$49.19 (+0.67%)
$51.26 (-3.39%)
SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Earnings decline YoY
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
SNY Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SNY Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displaySNY Earnings
The TTM reflects 12-month period, providing review of SNY financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
PFE
24.67
-0.22%
NVS
131.64
+0.15%
LLY
821.04
+1.06%
MRK
87.18
-0.55%
ABBV
228.25
-0.16%
What is SNY current stock price?
What are SNY stock strengths?
What risks are associated with SNY stock?
When is SNY next earnings report?
What is SNY market cap and volume?
What is SNY's current Stock IQ?
Should I buy SNY stock right now?
Is SNY a Strong Buy right now?
What does a 'Strong Buy' rating mean for SNY?
What does a 'Strong Sell' rating mean for SNY?
What factors influence SNY's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+5.62%
-3.26%
+11.27%
+19.34%
-2.31%
SNY
Sanofi
Current Price
$49.52
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value
Linked to SNY
PFE
24.67
-0.22%
NVS
131.64
+0.15%
LLY
821.04
+1.06%
MRK
87.18
-0.55%
ABBV
228.25
-0.16%
Chart
$45.54 (+8.74%)
$45.66 (+8.45%)
$49.19 (+0.67%)
$51.26 (-3.39%)
SNY Analysts Opinion
SNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Reported a strong earnings

Earnings decline YoY
Rating
Rating
Momentum
Momentum

Price value has negative momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Trading below its fair value
![]()
SNY Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SNY Street view is extremely bullish and have positive views on the near-term outlook
SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators

Investors losing confidence

Average key support and resistance price levels.
SNY Earnings
The TTM data reflects the most recent 12-month period, providing overview of SNY financial performance.
SNY Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SNY Latest Analysis
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy. ) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537 formerly known as INBRX-101) for alpha-1 antitrypsin .AATD causes emphysema when the body doesn’.t produce enough of the protective alpha-1 antitrypsin (AAT) protein leading to a breakdown of the lung’.s air sacs (alveoli).This genetic condition leads to the accumulation of enzymes such as neutro
Wed Oct 22, 2025
Sanofis Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study . (RTTNews) - Sanofi (SNY SNYNF SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537 formerly INBRX-101) in adults with alpha-1 antitrypsin deficiency (AATD) emphysema. The investigational recombinant human AAT-
Wed Oct 22, 2025
Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine . (RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compared to standard-dose flu vaccines.
Mon Oct 20, 2025
Sanofi: FDA Accepts SBLA For Tzield For Expedited Review . (RTTNews) - Sanofi (SNY) said the FDA has accepted for expedited review the supplemental biologics license application for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older recently diagnosed with stage 3 T1D.
Mon Oct 20, 2025
Sanofis Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease. On Friday the European Medicines Agency'.s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for ) Rezurock (belumosudil).The French drug maker was seeking approval for Rezurock for the third-line treatment of adults and pediatric patients with chronic .cGVHD is considered one of the leading causes of morbidity and late non-relapse mortality after stem cell transplant. Sanofi will seek a
Fri Oct 17, 2025
Sanofis Wayrilz Bags CHMP Recommendation For Immune Thrombocytopenia Treatment . (RTTNews) - Sanofi (SNY) Friday announced that the European Medicines Agencys Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Wayrilz for the treatment of immune thrombocytopenia in adults.
Fri Oct 17, 2025
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi. ...
Thu Oct 16, 2025
EVOQ Enters Collaboration And License Agreement With Sanofi . (RTTNews) - EVOQ Therapeutics Inc. announced a Collaboration and License Agreement with Sanofi (SNY). EVOQ is focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases. EVOQs technology platform utilizes a synthetic HDL NanoDisc that
Thu Oct 16, 2025
RVTY Collaborates With Sanofi for Early Detection of Type 1 Diabetes. Revvity partners with Sanofi to launch a scalable diagnostic test for early T1D detection expanding its reach beyond rare diseases.
Thu Oct 9, 2025
BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS. ) (FRA: 5LB) (OTCQB:) (".BioVaxys". or ".Company".) is pleased to announce that Dr. Tartaglia is an internationally recognized vaccine R&.D leader with over 34 years of industry experience including contributions to partnerships with private sector government and international agencies. Dr. Tartaglia recently retired as Global Head of Vaccine Development and Life Cycle Management for Sanofi the global p
Wed Oct 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.